D-2-Hydroxyglutarate dehydrogenase (D-2HGDH) catalyzes the specific and efficient oxidation of D-2-hydroxyglutarate (D-2HG) to 2-oxoglutarate using FAD as a cofactor. In this work, we demonstrate that D-2HGDH localizes to plant mitochondria and that its expression increases gradually during developmental and dark-induced senescence in Arabidopsis thaliana, indicating an enhanced demand of respiration of alternative substrates through this enzymatic system under these conditions. Using loss-of-function mutants in D-2HGDH (d2hgdh1) and stable isotope dilution LC-MS/MS, we found that the D-isomer of 2HG accumulated in leaves of d2hgdh1 during both forms of carbon starvation. In addition to this, d2hgdh1 presented enhanced levels of most TCA cycle intermediates and free amino acids. In contrast to the deleterious effects caused by a deficiency in D-2HGDH in humans, d2hgdh1 and overexpressing lines of D-2HGDH showed normal developmental and senescence phenotypes, indicating a mild role of D-2HGDH in the tested conditions. Moreover, metabolic fingerprinting of leaves of plants grown in media supplemented with putative precursors indicated that D-2HG most probably originates during the catabolism of lysine. Finally, the L-isomer of 2HG was also detected in leaf extracts, indicating that both chiral forms of 2HG participate in plant metabolism.
2-Hydroxyglutarate (2HG3 ; 2-hydroxypentanedioic acid) is a five-carbon dicarboxylic acid with the hydroxy group on the ␣-carbon. D-2HG accumulates in humans in the inherited neurometabolic disorder 2-hydroxyglutaric aciduria (2HGA) due to a deficiency in D-2HG dehydrogenase (D-2HGDH) (1), which converts D-2HG to 2-oxoglutarate (2OG); the electron transfer flavoprotein (ETF); or the ETF-ubiquinone oxidoreductase (ETFQO) (2), both electron acceptors of D-2HGDH (1). The clinical symptoms encompass developmental retardation, neurological dysfunction, and cerebral atrophy (1). In addition to high levels of 2HG, patients with 2HGA also have high concentrations of TCA cycle intermediates. On the other hand, excess accumulation of D-2HG contributes to the formation and malignant progression of brain tumors (3). Mutations in the cytosolic enzyme IDH1 (isocitrate dehydrogenase 1) occur in ϳ80% of secondary brain cancer tumors and in nearly onetenth of acute myelogenous leukemia tumors. Normally, IDH1 catalyzes the conversion of isocitrate to 2OG. Cancer-associated mutations in IDH1 reduce the affinity of the enzyme for isocitrate and increase the affinity for NADPH and 2OG. This prevents the oxidative decarboxylation of isocitrate to 2OG and facilitates the conversion of 2OG to D-2HG. In this way, IDH1 mutations cause a gain of function, resulting in the production and accumulation of D-2HG (3).D-2HG occurs in mammals (i) in the conversion of 2OG to D-2HG through a hydroxy acid-oxoacid transhydrogenase with the concomitant conversion of ␥-hydroxybutyrate to succinic semialdehyde (4), (ii) as an intermediate in the succinate-glycine cycle between 2OG semialdehyde and 2OG (5), and (iii) in ...